Talecris Biotherapeutics Study Demonstrates PROLASTIN®-C Is As Effective As PROLASTIN®
Links shared publicly online about this topic.
- 782total visits
Talecris Biotherapeutics Study Demonstrates PROLASTIN®-C Is As Effective As PROLASTIN®
View full resource at medicalnewstoday.com
Tags: Asthma
Most Recently Shared on October 22, 2010 at 8:05 pm By:
Talecris Biotherapeutics Study Demonstrates PROLASTIN®-C Is As Effective As PROLASTIN® http://mnt.to/3LCv #genetics
Also Shared By:
Integrated Analysis Demonstrates Alpha(1)-Augmentation Therapy Significantly Reduces Loss Of Lung Tissue In Patients With Deficiency-related Emphysema
medicalnewstoday.com — “Talecris Biotherapeutics (Nasdaq: TLCR) announced the publication of combined data from two studies demonstrating that augmentation therapy with Alpha(1)-Proteinase Inhibitor (Human) (A1PI) signif” View full resource at medicalnewstoday.com
Most Recently Shared on November 16, 2010 at 2:06 pm By:
MNT Pharma News Pharma and Health News
Integrated Analysis Demonstrates Alpha(1)-Augmentation Therapy Significantly Reduces Loss Of Lung Tissue In Patients W... http://mnt.to/3MDy
Talecris announces publication of A1PI studies for AAT deficiency in Respiratory Research journal
news-medical.net — “Talecris Biotherapeutics announced today the publication of combined data from two studies demonstrating that augmentation therapy with Alpha(1)-Proteinase Inhibitor (Human) (A1PI) significantly reduces lung tissue loss in patients with emphysema related to Alpha(1)-antitrypsin (AAT) deficiency.” View full resource at news-medical.net
Most Recently Shared on November 15, 2010 at 2:13 pm By:
Talecris announces publication of A1PI studies for AAT deficiency in Respiratory Research journal: Talecris Biot... http://bit.ly/c6hMtu
Talecris announces publication of A1PI studies for AAT deficiency in Respiratory Research journal
news-medical.net — “Talecris Biotherapeutics announced today the publication of combined data from two studies demonstrating that augmentation therapy with Alpha(1)-Proteinase Inhibitor (Human) (A1PI) significantly reduces lung tissue loss in patients with emphysema related to Alpha(1)-antitrypsin (AAT) deficiency.” View full resource at news-medical.net
Most Recently Shared on November 15, 2010 at 12:46 pm By:
Talecris announces publication of A1PI studies for AAT deficiency in Respiratory Research journal: Talecris Biot... http://bit.ly/9AKYoZ
Talecris announces publication of PROLASTIN-C study results for AAT deficiency in BML journal
news-medical.net — “Talecris Biotherapeutics today announced the publication of results from a study showing that PROLASTIN-C (Alpha1-Proteinase Inhibitor [Human]) (A1PI) is as effective as PROLASTIN (Alpha1-Proteinase Inhibitor [Human]) in raising levels of alpha-1 protein in patients with alpha1-antitrypsin (AAT) deficiency.” View full resource at news-medical.net
Most Recently Shared on October 22, 2010 at 9:34 am By:
Medicare News: Talecris announces publication of PROLASTIN-C study results for AAT deficiency in BML journal: Tale... http://bit.ly/9sPgSI
Advertisement
MNT Gastrointestinal
@mnt_gastro
Talecris Biotherapeutics Study Demonstrates PROLASTIN®-C Is As Effective As PROLASTIN® http://mnt.to/3LCv #gastrointestinal
1 year ago...